register free | resend password


Acquired Hemophilia Treatment Market 2017-2025 by Segmentation Based on Product, Application and Region

The acquired hemophilia treatment market was valued at USD 1,923.4 Mn in 2015, and is expected to reach USD 2,474.7 Mn by 2025, expanding at a CAGR of 3.2% from 2016 to 2025.

ID: 1529966
recent pressrelease next pressrelease

(businesspress24) - The latest market report published by Credence Research, Inc. 25.
Market Insights
According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Medical practitioners suggest that, acquired hemophilia can potentially cause life-threatening bleeding complications in severe cases and in around 50% of cases, there is an identifiable underlying clinical condition; in the other 50% no cause is known i.e. idiopathic. Treatment strategies that are applied against acquired hemophilia are based on two major objectives.
Browse the full report Acquired Hemophilia Treatment Market - Growth, Future Prospects, Competitive Analysis, 2016
The primary objective is effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is to eliminate the inhibitor and cure the disease. Thus, the global acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories such as traditional therapies and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment and immunomodulatory treatment. The advanced therapies is further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA. The advanced therapies held the largest segment due to introduction of novel therapies for the treatment of acquired hemophilia.
Geographically in 2015, constituted by regional markets of U.S. and Canada; North America stood out to be the clear leader in the global acquired hemophilia treatment market. North America dominated the market due to aging population, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. Moreover, in U.S. and Canada, the network of hemophilia care centers is well set with domestic government support. The primary management option is evolved in developed countries with early treatment of bleeding episodes and quick home therapy. Asia Pacific was observed as the attractive market in acquired hemophilia treatment due to emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis.


Market Competition Assessment:
The acquired hemophilia treatment market is observed to be majorly dominated by few players operating in the market. The market is dominated by players, depending on their major competencies. The key players in this market are Baxalta, Inc. (Shire), Novo Nordisk, Biogen, Pfizer, Inc., and F. Hoffman La Roche.
Key Market Movements:

Latest Reports:
Malt Ingredients Market: http://www.credenceresearch.com/report/malt-ingredients-market
Oral Care Market: http://www.credenceresearch.com/report/oral-care-market
About:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we''ve manufactured a firm extraordinarily prepared for this task.



More information:
http://www.credenceresearch.com/report/acquired-hemophilia-treatment-market



Keywords (optional):

acquired-hemophilia-treatment-market,



Company information / Profile:

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales(at)credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com

PressRelease by

Requests:



PressContact / Agency:

18003618290



published by: satyamspot
print pressrelease  send to a friend  

Date: 12/05/2017 - 06:58
Language: English
News-ID 1529966
Character count: 4830
Kontakt-Informationen:
Firma: Credence Research
Ansprechpartner: Robson Tolson Feedback to businesspress24.com about Pressrelease-id:
Stadt: SANJOSE
Telefon: 18003618290

Meldungsart: Unternehmensinformation
Versandart: Veröffentlichung
Freigabedatum: 5-12-2017
Comments:



Number of hits: 361

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 96


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.